PHILADELPHIA, Dec. 10, 2023 (GLOBE NEWSWIRE) — Kaskela Law LLC announces that it is investigating Acadia Pharmaceuticals Inc. (“Acadia”) (NASDAQ: ACAD) on behalf the company’s long-term investors.
Recently an amended securities fraud complaint was filed against Acadia on behalf of certain investors who purchased shares of the Company’s stock between September 9, 2019 and April 4, 2021. According to the complaint, Acadia’s most valuable drug from a commercial perspective is pimavanserin, which Acadia touts as a treatment for dementia-related psychosis (“DRP”).
Further according to the complaint, between September 9, 2019 and April 4, 2021, Acadia and certain of the company’s senior executive officers issued a series of false and misleading statements concerning Acadia’s HARMONY trial, which had been designed to study the greatly expanded use of pimavanserin.
On March 8, 2021, Acadia disclosed that it “received a notification from the U.S. Food and Drug Administration (FDA) on March 3, 2021, stating that, as part of its ongoing review of the Company’s supplemental New Drug Application (sNDA), the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time.” Following this news, shares of Acadia’s common stock fell $20.76 per share, or over 45% in value, to close on March 9, 2021 at $25.02 per share, on heavy trading volume.
Then, on April 5, 2021, Acadia disclosed that it had received a Complete Response Letter (CRL) from the FDA regarding the sNDA “to indicate that they have completed their review of the application and has determined that the application cannot be approved in its present form.” The press release further disclosed that “the [FDA Division of Psychiatry], in the CRL, cited a lack of statistical significance in some of the subgroups of dementia, and insufficient numbers of patients with certain less common dementia subtypes as lack of substantial evidence of effectiveness to support approval.” Following this additional news, shares of Acadia’s common stock fell an additional $4.41 per share, or over 17% in value, to close on April 5, 2021 at $21.18 per share, again on heavy trading volume.
Current Acadia stockholders who purchased or acquired shares of the company’s common stock prior to September 9, 2019 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750, or by email (skaskela@kaskelalaw.com / abell@kaskelalaw.com) or online at https://kaskelalaw.com/cases/acadia-pharmaceuticals/ , for additional information about this investigation and their legal rights and options.
Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com. This notice may constitute attorney advertising in certain jurisdictions.
CONTACT:
KASKELA LAW LLC
D. Seamus Kaskela, Esq.
Adrienne Bell, Esq.
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(888) 715 – 1740
(484) 229 – 0750
www.kaskelalaw.com
- HostColor Expands Its AMD Dedicated Server Offerings in LA and New York - June 14, 2025
- Nuclear Air Filtration for HVAC Managers: Why the Nuclear Comeback Demands Next-Gen Filtration Standards - June 14, 2025
- THREE Business Insurance Provides Valuable Information on Proven Strategies for Restaurant Risk Management - June 14, 2025
